Nicholas C. Turner, MD, PhD, on Tackling Breast Cancer Diversity
2017 San Antonio Breast Cancer Symposium
Nicholas C. Turner, MD, PhD, of The Royal Marsden Hospital NHS Trust, discusses the challenges of treating metastatic breast cancer and how liquid biopsies can serve as a guide to genetic phenotypes.
Wolfgang Janni, MD, PhD, of Ulm University, discusses study findings that showed extended adjuvant bisphosphonate treatment over 5 years in early breast cancer does not improve disease-free and overall survival when compared with 2 years of treatment (Abstract GS1-06).
Eric S. Winer, MD, of the Dana-Farber Cancer Institute, addresses the much-discussed controversy over whether all women diagnosed with metastatic breast cancer should undergo next-generation sequencing.
Louis Fehrenbacher, MD, of Kaiser Permanente, discusses study findings comparing adjuvant chemotherapy with doxorubicin and cyclophosphamide followed by weekly paclitaxel—or docetaxel and cyclophosphamide—with or without a year of trastuzumab in women with node-positive or high-risk node-negative disease (Abstract GS1-02).
Rowan T. Chlebowski, MD, PhD, of the City of Hope National Medical Center, discusses 11-year followup results that showed a significantly lower breast cancer incidence among women with a greater than 5% weight loss (Abstract GS5-07).
Elizabeth A. Mittendorf, MD, PhD, of The University of Texas MD Anderson Cancer Center, discusses the growing role of immunotherapy in treating breast disease, the evidence of biomarkers that may be associated with response to therapy, and the opportunities to perform robust correlative studies.